• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
LEQSELVI

In the United States, Sun Pharma Announces the Launch of LEQSELVI™ (deuruxolitinib) for the Treatment of Severe Alopecia Areata

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced LEQSELVI™ (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S. LEQSELVI is indicated for the treatment of adults with severe alopecia areata.

Read more →
Tru Niagen

At Equinox Hotel New York, Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through NutriDrip

Read more →
Monjuvi vial and box

Incyte announces FDA approval of Monjuvi® (tafasitamab-cxix) with Rituximab and Lenalidomide for relapsed or refractory follicular lymphoma

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Read more →
Clareon® PanOptix® Pro

Alcon unveils the Clareon PanOptix Pro in Canada, setting a new standard with the lowest light scatter of any trifocal IOL

Alcon the global leader in eye care dedicated to helping people see brilliantly, announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.

Read more →
STEMCELL

Stemcell Technologies and CollPlant expand their collaboration

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen)  for tissue regeneration and medical aesthetics, announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences.

Read more →
biocrates kits and pipettes

Bruker Acquires biocrates, a Leader in Quantitative Metabolomics

Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. Biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide.

Read more →
RECIPE kits for clinical laboratories

Bruker Applied MS Unveils Launches timsMetabo™ for PFAS Detection, and Highlights DART Advances for TDM and DoA

Bruker Corporation announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.

Read more →